Phase 2b study of ALG-055009
Latest Information Update: 24 Sep 2024
Price :
$35 *
At a glance
- Drugs ALG 055009 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 24 Sep 2024 New trial record
- 19 Sep 2024 According to an Aligos Therapeutics media release, company is planning to complete the activities required for a Phase 2b study by the middle of 2025 and are assessing potential Phase 2b clinical trial designs.